Trial Profile
Efficacy and safety of semaglutide once-weekly versus placebo in drug-naive subjects with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN 1
- Sponsors Novo Nordisk
- 26 Jun 2023 Results assessing proportion of participants treated with once-weekly semaglutide, or a comparator, achieving a metabolic composite target endpoint from SUSTAIN trials (1 - 5 and 7 - 10) and SUSTAIN China presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 29 Jun 2021 Results of post-hoc analysis of SUSTAIN1-5 & 7-10 presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 25 Sep 2020 Results (n=9680) of analysis from twelve clinical studies: SUSTAIN 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 and two Japanese SUSTAIN trials assessing risk predictors for Gastrointestinal adverse events with once weekly subcutaneous Semaglutide identifying high-risk patients presented at the 56th Annual Meeting of the European Association for the Study of Diabetes